Portal de Periódicos da CAPES

Infant Hospitalizations and Mortality After Maternal Vaccination

2018; American Academy of Pediatrics; Volume: 141; Issue: 3 Linguagem: Inglês

10.1542/peds.2017-3310

1098-4275

Lakshmi Sukumaran, Natalie McCarthy, Elyse O. Kharbanda, Gabriela Vazquez‐Benitez, Heather S. Lipkind, Lisa A. Jackson, Nicola P. Klein, Allison L. Naleway, David L. McClure, Rulin C. Hechter, Alison Tse Kawai, Jason M. Glanz, Eric Weintraub,

COVID-19 Impact on Reproduction

Article| March 01 2018 Infant Hospitalizations and Mortality After Maternal Vaccination Lakshmi Sukumaran, MD; Lakshmi Sukumaran, MD aImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia; Address correspondence to Lakshmi Sukumaran, MD, MPH, Immunization Safety Office, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS D-26, Atlanta, GA 30333. E-mail: lsukumaran@cdc.gov Search for other works by this author on: This Site PubMed Google Scholar Natalie L. McCarthy, MPH; Natalie L. McCarthy, MPH aImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia; Search for other works by this author on: This Site PubMed Google Scholar Elyse O. Kharbanda, MD; Elyse O. Kharbanda, MD bHealthPartners Institute, Minneapolis, Minnesota; Search for other works by this author on: This Site PubMed Google Scholar Gabriela Vazquez-Benitez, PhD; Gabriela Vazquez-Benitez, PhD bHealthPartners Institute, Minneapolis, Minnesota; Search for other works by this author on: This Site PubMed Google Scholar Heather S. Lipkind, MD; Heather S. Lipkind, MD cDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, Yale University, New Haven, Connecticut; Search for other works by this author on: This Site PubMed Google Scholar Lisa Jackson, MD; Lisa Jackson, MD dKaiser Permanente Washington Health Research Institute, Seattle, Washington; Search for other works by this author on: This Site PubMed Google Scholar Nicola P. Klein, MD; Nicola P. Klein, MD eDivision of Research, Kaiser Permanente of Northern California, Oakland, California; Search for other works by this author on: This Site PubMed Google Scholar Allison L. Naleway, PhD; Allison L. Naleway, PhD fCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; Search for other works by this author on: This Site PubMed Google Scholar David L. McClure, PhD; David L. McClure, PhD gMarshfield Clinic Research Institute, Marshfield, Wisconsin; Search for other works by this author on: This Site PubMed Google Scholar Rulin C. Hechter, MD; Rulin C. Hechter, MD hDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Search for other works by this author on: This Site PubMed Google Scholar Alison T. Kawai, ScD; Alison T. Kawai, ScD iDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; and Search for other works by this author on: This Site PubMed Google Scholar Jason M. Glanz, PhD; Jason M. Glanz, PhD jInstitute for Health Research, Kaiser Permanente Colorado, Denver, Colorado Search for other works by this author on: This Site PubMed Google Scholar Eric S. Weintraub, MPH Eric S. Weintraub, MPH aImmunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia; Search for other works by this author on: This Site PubMed Google Scholar Address correspondence to Lakshmi Sukumaran, MD, MPH, Immunization Safety Office, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS D-26, Atlanta, GA 30333. E-mail: lsukumaran@cdc.gov POTENTIAL CONFLICT OF INTEREST: Dr Klein has received research support from GlaxoSmithKline, Sanofi Pasteur, Protein Science, Pfizer, Merck & Co., MedImmune, and Dynavax. Dr Naleway has received research support from Merck, Pfizer, and MedImmune for unrelated studies; the other authors have indicated they have no potential conflicts of interest to disclose. FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose. Pediatrics (2018) 141 (3): e20173310. https://doi.org/10.1542/peds.2017-3310 Article history Accepted: December 01 2017 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Lakshmi Sukumaran, Natalie L. McCarthy, Elyse O. Kharbanda, Gabriela Vazquez-Benitez, Heather S. Lipkind, Lisa Jackson, Nicola P. Klein, Allison L. Naleway, David L. McClure, Rulin C. Hechter, Alison T. Kawai, Jason M. Glanz, Eric S. Weintraub; Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics March 2018; 141 (3): e20173310. 10.1542/peds.2017-3310 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search toolbar search search input Search input auto suggest filter your search All PublicationsAll JournalsPediatricsHospital PediatricsPediatrics In ReviewNeoReviewsAAP Grand RoundsAAP NewsAll AAP Sites Search Advanced Search BACKGROUND:The Advisory Committee on Immunization Practices currently recommends pregnant women receive influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines. There are limited studies of the long-term safety in infants for vaccines administered during pregnancy. We evaluate whether maternal receipt of influenza and Tdap vaccines increases the risk of infant hospitalization or death in the first 6 months of life.METHODS:We included singleton, live birth pregnancies in the Vaccine Safety Datalink between 2004 and 2014. Outcomes were infant hospitalizations and mortality in the first 6 months of life. We performed a case-control study matching case patients and controls 1:1 and used conditional logistic regression to estimate odds ratios for maternal exposure to influenza and/or Tdap vaccines in pregnancy.RESULTS:There were 413 034 live births in our population. Of these, 25 222 infants had hospitalizations and 157 infants died in the first 6 months of life. We found no association between infant hospitalization and maternal influenza (adjusted odds ratio: 1.00; 95% confidence interval [CI]: 0.96–1.04) or Tdap (adjusted odds ratio: 0.94; 95% CI: 0.88–1.01) vaccinations. We found no association between infant mortality and maternal influenza (adjusted odds ratio: 0.96; 95% CI: 0.54–1.69) or Tdap (adjusted odds ratio: 0.44; 95% CI: 0.17–1.13) vaccinations.CONCLUSIONS:We found no association between vaccination during pregnancy and risk of infant hospitalization or death in the first 6 months of life. These findings support the safety of current recommendations for influenza and Tdap vaccination during pregnancy. Subjects: Gynecology, Infectious Diseases, Maternal and Fetal Medicine, Vaccine/Immunization Topics: influenza, tdap vaccine, vaccination, vaccines, ventricular septal defect, pertussis, diphtheria vaccine, tetanus toxoid, influenza vaccines, vaccine safety Copyright © 2018 by the American Academy of Pediatrics2018 You do not currently have access to this content.